COVID-19-associated coagulopathy in children: A multicenter observational cohort study

Pediatr Blood Cancer. 2023 Jan;70(1):e30079. doi: 10.1002/pbc.30079. Epub 2022 Nov 3.

Abstract

SARS-CoV-2 infection (coronavirus disease 2019 [COVID-19]) induces a stark procoagulant state, with many hospitalized adults developing thrombosis despite prophylactic anticoagulation. This study aimed to characterize hemostatic parameters and associated clinical outcomes of COVID-19, such as thrombosis and bleeding, in children and to assess thromboprophylaxis use. This multicenter observational cohort study included 79 patients aged up to 18 years admitted to all pediatric hospitals in Québec, Canada, with SARS-CoV-2 infection during a 5-month period. D-dimers were elevated in 18/19 patients (94.7%) and fibrinogen in 15/26 patients (60%). Eleven patients (13.9%) received anticoagulant thromboprophylaxis. One thrombotic event and one major bleed were observed.

Keywords: COVID-19; children; coagulopathy; thromboprophylaxis; thrombosis.

Publication types

  • Multicenter Study
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anticoagulants / therapeutic use
  • Blood Coagulation Disorders* / chemically induced
  • Blood Coagulation Disorders* / etiology
  • COVID-19* / complications
  • Child
  • Hemorrhage / drug therapy
  • Humans
  • SARS-CoV-2
  • Thrombosis* / drug therapy
  • Venous Thromboembolism* / drug therapy

Substances

  • Anticoagulants